26 May 2013
Keywords: renovis, ph, ii, trial, phn, drug, misses
Article | 14 March 2005
California, USA-headquartered Renovis says it is terminating development of REN-1654 for the treatment of post-herpetic neuralgia after results
from a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 March 2005
7 March 2005
24 May 2013
© 2013 thepharmaletter.com